antibody

Goat anti-LIVIN/BIRC7 Antibody

MBS420120

0.1 mg

300 USD

polyclonal

goat

nonconjugated

western blot, enzyme immunoassay

Antibody

Goat anti-LIVIN/BIRC7 Antibody

LIVIN/BIRC7

BIRC7; LIVIN; baculoviral IAP repeat-containing 7 (livin); KIAP; MLIAP; mliap; ML-IAP; livin inhibitor-of-apotosis; kidney inhibitor of apoptosis protein; melanoma inhibitor of apoptosis protein; baculoviral IAP repeat-containing protein 7; RNF50; livin i; BIRC7 antibody; LIVIN antibody; baculoviral IAP repeat-containing 7 (livin) antibody; KIAP antibody; MLIAP antibody; mliap antibody; ML-IAP antibody; livin inhibitor-of-apotosis antibody; kidney inhibitor of apoptosis protein antibody; melanoma inhibitor of apoptosis protein antibody; baculoviral IAP repeat-containing protein 7 antibody; RNF50 antibody; livin inhibitor of apoptosis antibody; LIVIN / BIRC7

baculoviral IAP repeat-containing protein 7 isoform alpha; Baculoviral IAP repeat-containing protein 7; baculoviral IAP repeat-containing protein 7; baculoviral IAP repeat containing 7; Kidney inhibitor of apoptosis protein; KIAP

BIRC7

LIVIN

BIRC7; BIRC7; KIAP; LIVIN; MLIAP; RNF50; ML-IAP; KIAP; LIVIN; MLIAP; RNF50; KIAP; ML-IAP; Truncated livin; p30-Livin; tLivin

BIRC7_HUMAN

Polyclonal

Goat

Tested: Human; Expected from sequence similarity: Human

298

RAPVRSRVRT

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Peptide ELISA (EIA), Western Blot (WB)

Peptide ELISA: Antibody detection limit dilution 1: 4000. Western Blot: Approx 30kDa and 35kDa in lysates of celkl line Molt4, and 30kDa in lysates of Daudi, Jurkat and K562. These bands correspond to the reported isoforms with calculated MW of 32.8kDa according to NP_647478.1 and 30.9kDa according to NP_071444.1. Recommended concentration: 0.3 - 1 ug/ml.

Immunogen: Peptide with sequence C-RAPVRSRVRT, from the C Terminus of the protein sequence according to NP_647478.1; NP_071444.1. Epitope: C Terminus

Note: This antibody is expected to recognise both reported isoforms (as represented by NP_647478.1 and NP_071444.1)

21536421

NP_647478.1

NM_139317.2

30,866 Da

Apoptosis - Multiple Species Pathway (1384747); Apoptosis - Multiple Species Pathway (1384709); Apoptosis Modulation And Signaling Pathway (198822); Pathways In Cancer (83105); Small Cell Lung Cancer Pathway (83118); Small Cell Lung Cancer Pathway (530); Toxoplasmosis Pathway (169642); Toxoplasmosis Pathway (169493); Ubiquitin Mediated Proteolysis Pathway (83056); Ubiquitin Mediated Proteolysis Pathway (466)

This gene encodes a member of the inhibitor of apoptosis protein (IAP) family, and contains a single copy of a baculovirus IAP repeat (BIR) as well as a RING-type zinc finger domain. The BIR domain is essential for inhibitory activity and interacts with caspases, while the RING finger domain sometimes enhances antiapoptotic activity but does not inhibit apoptosis alone. Elevated levels of the encoded protein may be associated with cancer progression and play a role in chemotherapy sensitivity. Alternative splicing results in multiple transcript variants [provided by RefSeq, Jul 2013]

BIRC7: Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control. Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity. As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival. May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions. Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine. Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2. This activation depends on TAB1 and NR2C2/TAK1. In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9. Isoform 1 blocks staurosporine-induced apoptosis. Isoform 2 blocks etoposide-induced apoptosis. Isoform 2 protects against natural killer (NK) cell killing whereas isoform 1 augments killing. Binds to CASP9. Interaction with DIABLO/SMAC via the BIR domain disrupts binding to CASP9 and apoptotic suppressor activity. Interacts with TAB1. In vitro, interacts with CASP3 and CASP7 via its BIR domain. Isoform 1 and isoform 2 are expressed at very low levels or not detectable in most adult tissues. Detected in adult heart, placenta, lung, lymph node, spleen and ovary, and in several carcinoma cell lines. Isoform 2 is detected in fetal kidney, heart and spleen, and at lower levels in adult brain, skeletal muscle and peripheral blood leukocytes. Belongs to the IAP family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Apoptosis; Ubiquitin ligase; Ubiquitin conjugating system; EC 6.3.2.-; Ligase. Chromosomal Location of Human Ortholog: 20q13.3. Cellular Component: cytoplasm; Golgi apparatus; nucleus; spindle microtubule. Molecular Function: cysteine protease inhibitor activity; enzyme binding; ligase activity; protein binding; ubiquitin-protein ligase activity; zinc ion binding. Biological Process: activation of JNK activity; negative regulation of apoptosis; protein ubiquitination; regulation of cell proliferation; regulation of signal transduction

0.1 mg

300 USD